In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

Sarfaraz K. Niazi, PhD, dives into the role that biosimilar associations and organizations play in promoting biosimilars as ...

A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid ...

Number 4: Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the ...

The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...

Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access ...

The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer ...

Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

Reforming patent litigation to mirror successful outcomes across Europe could significantly accelerate US biosimilar market ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...